Kite Pharma's newly approved blood cancer treatment, Yescarta, uses gene therapy techniques not to fix disease-causing genes but to turbocharge T cells, immune system soldiers that cancer can often evade.
There has been heightened scrutiny over pharmacy benefit managers' role in drug pricing in recent years. Anthem's creation of its own pharmacy benefit management company could drive change throughout the industry as health plans and PBMs aim to maintain their competitive edge, experts said.
HHS' OIG called on the CMS to collect medical-device specific information as part of its claims process, a move that could help the agency quickly identify poorly performing devices.
Norman Regional Health System is bundling its equipment purchasing to reduce costs and improve care.